LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

NCT01856478 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

340

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Neoplasms

Interventions

DRUG: Methotrexate
DRUG: Afatinib

Sponsor

Boehringer Ingelheim